Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection

Table 1 Demographic characteristics of the study population n (%)

	1-wk MCT	2-wk MCT
No. of patients	60	38
Age (mean ± SD), yr	55.5 ± 9.9	59.4 ± 11.7
Sex (male/female), n	28/32	23/15
Comorbidity
Hypertension	10 (16.7)	11 (28.9)
Diabetes	2 (3.3)	5 (13.2)
Current smoking	4 (6.7)	4 (10.5)
Alcohol intake	10 (16.7)	7 (18.4)
Endoscopic diagnosis
HPAG	51 (85.0)	29 (76.3)
GU	1 (1.7)	2 (5.3)
DU	7 (11.7)	5 (13.2)
GU + DU	1 (1.7)	2 (5.3)

MCT: Moxifloxacin-containing triple therapy; HPAG: Helicobacter pylori-associated gastritis; GU: Gastric ulcer; DU: Duodenal ulcer.

Table 2 Outcomes of 1-wk and 2-wk moxifloxacin-containing triple therapy n (%)

	1-wk MCT	2-wk MCT	P value
Eradication rate
Intention-to-treat	34 (56.7)	29 (76.3)	0.048
Per-protocol	34 (59.6)	29 (80.6)	0.036
Compliance	57 (95.0)	36 (94.9)	0.954
Side effects	12 (21.1)	5 (13.9)	0.384
Nausea	5 (11.6)	0	0.178
Dyspepsia	4 (7.0)	1 (2.8)
Epigastric soreness	2 (3.5)	1 (2.8)
Diarrhea	1 (1.8)	3 (8.3)

MCT: Moxifloxacin-containing triple therapy.

Table 3 Univariate analysis of the clinical factors influencing the efficacy of moxifloxacin-containing triple therapy

Clinical factor	No. patients	Eradication rate	P value
Age, yr
≤ 60	60	61.7%	0.497
> 60	38	68.4%
Sex
Female	47	66.0%	0.740
Male	51	62.7%
Alcohol
No	81	65.4%	0.605
Yes	17	58.8%
Smoking
No	90	64.4%	1.000
Yes	8	62.5%
Hypertension
No	77	63.6%	0.797
Yes	21	66.7%
Diabetes
No	91	62.6%	0.416
Yes	7	85.7%
Gastric ulcer
No	92	64.1%	1.000
Yes	6	66.7%
Duodenal ulcer
No	83	63.9%	0.834
Yes	15	66.7%
First regimen
10-d ST	30	50.0%	0.138
2-wk ST	25	68.0%
2-wk CT	43	72.1%
Second regimen
1-wk MCT	60	56.7%	0.048
2-wk MCT	38	76.3%

ST: Sequential therapy; CT: Concomitant therapy; MCT: Moxifloxacin-containing triple therapy.